Keywords: Abbott Labs, Kaletra, Global campaign, Monopoly, Pricing, AIDS medicine

Public health groups launch global campaign against Abbott Labs’ monopoly on critical AIDS medicine

Article | 11 November 2011

Print This

A global campaign to challenge US health care major Abbott Laboratories’ (NYSE: ABT) monopolistic hold on Kaletra (lopinavir+ritonavir), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in